Mirae Asset Global Investments Co. Ltd. Has $20.46 Million Stock Holdings in Pfizer Inc. $PFE

Key Points

• Mirae Asset Global Investments has increased its holdings in Pfizer by 4.2%, owning 843,894 shares valued at approximately $20.46 million after a recent purchase.
• Institutional investors collectively hold 68.36% of Pfizer's stock, with notable increases in holdings from firms like Pacer Advisors (up 856.8%) and Goldman Sachs (up 51.9%).
• Analysts have set a consensus price target of $28.41 for Pfizer, with a mix of ratings including two Strong Buy, four Buy, and twelve Hold ratings.

Mirae Asset Global Investments Co. Ltd. increased its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 4.2% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 843,894 shares of the biopharmaceutical company's stock after buying an additional 34,101 shares during the quarter. Mirae Asset Global Investments Co. Ltd.'s holdings in Pfizer were worth $20,456,000 at the end of the most recent quarter.

A number of other institutional investors also recently added to or reduced their stakes in PFE. Pacer Advisors Inc. boosted its holdings in Pfizer by 856.8% during the first quarter. Pacer Advisors Inc. now owns 20,053,828 shares of the biopharmaceutical company's stock valued at $508,164,000 after purchasing an additional 17,957,928 shares in the last quarter. Amundi boosted its holdings in Pfizer by 43.4% during the first quarter. Amundi now owns 52,090,403 shares of the biopharmaceutical company's stock valued at $1,265,277,000 after purchasing an additional 15,758,846 shares in the last quarter. Nuveen LLC acquired a new stake in Pfizer during the first quarter valued at approximately $389,861,000. Goldman Sachs Group Inc. boosted its holdings in shares of Pfizer by 51.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 26,456,457 shares of the biopharmaceutical company's stock worth $670,407,000 after acquiring an additional 9,041,990 shares in the last quarter. Finally, Assenagon Asset Management S.A. boosted its holdings in shares of Pfizer by 307.5% in the 1st quarter. Assenagon Asset Management S.A. now owns 10,046,340 shares of the biopharmaceutical company's stock worth $254,574,000 after acquiring an additional 7,581,030 shares in the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

PFE has been the topic of several recent analyst reports. UBS Group reissued a "neutral" rating and issued a $28.00 target price on shares of Pfizer in a report on Wednesday. Bank of America boosted their target price on Pfizer from $28.00 to $30.00 and gave the stock a "neutral" rating in a report on Friday. Morgan Stanley boosted their target price on Pfizer from $32.00 to $33.00 and gave the stock an "equal weight" rating in a report on Wednesday, August 6th. Weiss Ratings reissued a "hold (c-)" rating on shares of Pfizer in a report on Saturday, September 27th. Finally, Citigroup boosted their target price on Pfizer from $25.00 to $26.00 and gave the stock a "neutral" rating in a report on Wednesday, August 6th. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have given a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, Pfizer has a consensus rating of "Hold" and a consensus price target of $28.41.

Pfizer Stock Performance

PFE stock opened at $27.37 on Friday. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. The company has a 50 day moving average price of $24.67 and a 200 day moving average price of $24.15. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $30.43. The stock has a market capitalization of $155.59 billion, a PE ratio of 14.56, a price-to-earnings-growth ratio of 0.88 and a beta of 0.55.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.58 by $0.20. The firm had revenue of $14.65 billion during the quarter, compared to analysts' expectations of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. Pfizer's revenue was up 10.3% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.